Zuckerman Investment Group LLC boosted its stake in BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 346.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,000 shares of the company's stock after purchasing an additional 51,991 shares during the period. Zuckerman Investment Group LLC owned about 0.36% of BrainsWay worth $667,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of BWAY. Phoenix Financial Ltd. raised its position in BrainsWay by 100.8% during the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after purchasing an additional 242,366 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of BrainsWay by 61.9% during the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock valued at $226,000 after buying an additional 9,149 shares during the period. Sei Investments Co. bought a new position in shares of BrainsWay during the fourth quarter valued at approximately $149,000. ARK Investment Management LLC bought a new position in shares of BrainsWay during the fourth quarter valued at approximately $1,656,000. Finally, Rhumbline Advisers lifted its stake in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after acquiring an additional 2,144 shares during the period. Institutional investors own 30.11% of the company's stock.
BrainsWay Price Performance
BWAY stock traded up $0.20 during midday trading on Tuesday, hitting $8.52. The stock had a trading volume of 9,359 shares, compared to its average volume of 72,593. The firm has a market cap of $160.76 million, a price-to-earnings ratio of 85.21 and a beta of 1.17. The business has a 50-day moving average of $9.79 and a two-hundred day moving average of $9.83. BrainsWay Ltd. has a 52-week low of $4.61 and a 52-week high of $11.79.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a report on Wednesday, March 12th.
View Our Latest Research Report on BrainsWay
BrainsWay Company Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
